Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
alpha-gal glycolipids (AGI-134) / BioLineRx
2018-001032-22: Safety and tolerability of AGI-134 in patients with solid tumours.	Not yet recruiting	1/2	55	Europe	AGI-134, Solution for injection	Agalimmune Ltd., Agalimune Ltd.	metastatic unresectable solid tumours, Solid tumors, Diseases [C] - Cancer [C04]
NCT03593226 / 2018-001032-22: Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour Jul 2019 - Dec 2019 : Initial safety data in combination with AGI-134 for solid tumors	Completed	1/2	40	Europe, US, RoW	AGI-134	Agalimmune Ltd., Agalimune Ltd.	Superficial, Palpable, Unresectable/Metastatic Solid Tumour	12/23	12/23